The Colon Club

This co-development deal announced between BMS (maker of Opdivo (nivolumab)) and Five Prime Therapeutics is a PD-1 combo trial I am watching closely & crossing fingers for MSS CRC. It combines a PD-1 inhibitor with a drug called FPA008 which blocks something called CSF1R.

http://www.businesswire.com/news/home/2 ... h9lf75Aw20

Scientists hope that blocking CSF1R would remove immunosupression from the "tumor microenvironment" - and make "cold tumors" (e.g. MSS-CRC tumors are "cold") more "hot" i.e. able to be attacked by the immune system. This is a subject I wrote about in a general way here: http://fightcolorectalcancer.org/resear ... ot-part-1/

Here is the link to the Phase 1 trial. As far as I know it is open to both MSI and MSS CRC patients. It just started in TX - they are planning a big trial so I am sure multiple additional sites will be opening soon.
https://clinicaltrials.gov/ct2/show/NCT ... 008&rank=1

This is a Phase 1 trial so no clinical data that it works yet - but from a purely scientific point of view, I think worthy of keeping a very close eye on!

-DK

Thanks for the information, Tom! My DH is currently taking the TAS-102 drug and is tolerating it well so far, but we continue to look for new options in the future!

I really don't know what can we do without you DK37. Thank you very much for keeping us up to date with these trials.

Awesome! Thanks!

Yes thank you for sharing your knowledge and educating me.